Randomized trial simulator: anti-NGF therapy vs placebo for knee/hip osteoarthritis pain
Screening identifies moderate-to-severe OA patients failing standard pain therapy.
Adults with chronic knee or hip OA pain qualify. Radiographs must confirm moderate-to-severe joint damage. Prior NSAID or opioid therapy must have failed.
Baseline WOMAC pain scores average sixty-five of one hundred. Daily pain limits walking, stairs, and standing. Patients report OA pain as their top burden.
Informed consent covers joint safety monitoring requirements. Joint imaging rules out rapidly progressive OA risk. Cardiovascular and neurologic history are also reviewed.
Enrolled patients are randomly assigned to anti-NGF or placebo.
A computer-generated sequence assigns each patient an arm. Stratification balances baseline pain severity across both arms. Site staff cannot predict the next assignment.
Neither patients nor assessors know arm assignment. Identical-looking injections prevent expectation bias in reporting. Unblinding only occurs for safety emergencies.
OA pain fluctuates and responds strongly to placebo. A control arm isolates the true drug effect. Without it, natural improvement could be misread as efficacy.
Patients receive scheduled doses and follow-up visits over months.
Anti-NGF antibody is injected subcutaneously every eight weeks. Placebo patients receive an identical-appearing injection schedule. Doses are weight-based and pharmacist-prepared.
Joint exams screen for rapidly progressive OA changes. Patients report numbness, tingling, or new joint symptoms. Sympathetic nervous system side effects are tracked closely.
Diaries capture daily pain and rescue medication use. Missed visits are minimized through patient reminder calls. High retention preserves statistical power at endpoint.
Pain and physical function are measured at the endpoint visit.
Five questions score pain during walking, stairs, and rest. Scores range zero to one hundred, lower is better. Change from baseline is the primary endpoint.
Seventeen items assess daily activities like rising and bathing. Function score change is the key co-primary endpoint. Both scales are patient-reported and validated.
A mixed model compares arms while accounting for dropouts. Significance is set at a two-sided p<0.05. Effect size is also reported for clinical relevance.
The anti-NGF arm shows significantly greater pain and function gains.
Anti-NGF patients report much larger pain score drops. Function gains are roughly double the placebo arm. Differences reach statistical and clinical significance.
A small subset shows rapidly progressive joint damage. Regulators require joint imaging monitoring after approval. Dose and duration limits reduce this risk.
Positive results support regulatory submission for approval. Long-term extension studies track durability and safety. Real-world registries will monitor joint outcomes further.